Bioxyne reports Phase IIb COPD data for HI-164OV

Bioxyne Ltd. (ASX:BXN) reported preliminary data from the Phase IIb HI-H005 trial to treat moderate to severe chronic obstructive pulmonary disease (COPD) showing that oral HI-164OV did not reduce the...